Chronic Urticaria: Long-Lasting Hives Management

Clinical Overview

Chronic Urticaria (CU) is characterized by recurrent wheals, angioedema, or both for >6 weeks, occurring spontaneously without clear identifiable triggers in 95% of cases (termed "chronic spontaneous urticaria"). Patients experience nearly daily symptoms over months to years, significantly impacting quality of life, work productivity, and mental health. Unlike acute urticaria (self-limited for 4-6 weeks), CU is a long-term condition requiring sustained management. The disease is treatable, though approximately 50% of patients have resolution by year 5, while others may have symptoms for decades.

Epidemiology & Risk Factors

CU affects 0.5-1% of the general population, with higher prevalence in women (female:male ratio 2:1). Peak incidence occurs at ages 40-60 years. The condition accounts for significant healthcare burden: in the US, patients with CU spend >$5 billion annually on healthcare. CU is associated with autoimmune thyroid disease (present in 30-60% of patients with positive TPO antibodies), though thyroid dysfunction is not always clinically evident. Helicobacter pylori infection has variable association depending on geographic region. Most cases (>95%) have no identifiable external trigger; extensive testing for food/environmental allergies is typically unrevealing and not recommended by AAD guidelines. Approximately 50% of patients have autoimmune features: circulating IgG autoantibodies against IgE receptor or IgE itself (positive autologous serum skin test in 30-50%). Female gender, older age, and presence of angioedema are associated with worse prognosis and longer disease duration.

Pathophysiology

CU involves dysregulated mast cell and basophil activation, though triggers vary. In autoimmune urticaria (40-50% of cases), IgG autoantibodies targeting high-affinity IgE receptor (FceRI) or IgE itself directly activate mast cells and basophils. Non-autoimmune cases (50-60%) involve intrinsic mast cell dysfunction: basophils and mast cells show exaggerated responsiveness to stimuli (lower activation threshold). Thyroid peroxidase (TPO) antibodies may cross-react with mast cell antigens, explaining the thyroid association. Genetic polymorphisms in mast cell activation pathways (TSLP, PAR-2) increase susceptibility. Proinflammatory mediators released by activated mast cells and basophils (histamine, tryptase, prostaglandin D2, leukotriene C4) cause vasodilation, endothelial permeability, and smooth muscle contraction, resulting in wheals and angioedema. IL-6, IL-8, and TNF-alpha perpetuate cutaneous and systemic inflammation.

Clinical Presentation & Classification

CU presents as recurrent wheals (urticaria): pruritic, erythematous, evanescent lesions that blanch with pressure and resolve without scarring, typically within 24 hours. Individual lesions may appear and disappear over hours. Angioedema (deeper, non-blanching swelling of skin and mucous membranes) occurs in 30-50% of patients, lasting hours to days. Symptoms are typically worst in early morning and evening. Disease activity fluctuates: some patients experience daily symptoms, while others have symptom-free periods interspersed with flares lasting days to weeks. Uncommon features include systemic symptoms (malaise, arthralgia, fever <38°C), though prominent systemic symptoms or fever should prompt evaluation for underlying systemic disease (serum sickness, vasculitis).

Urticaria Activity Score (UAS7): Validated scoring system where patients score daily itch (0-3) and hive count (0-3), summed over 7 days. Score 0-6 indicates mild disease, 7-15 moderate, 16-21 severe, 28-42 very severe. Used to assess severity and response to treatment.

Diagnosis & Workup

Diagnosis is primarily clinical based on characteristic wheals present for >6 weeks. Laboratory testing is minimal: basic metabolic panel and CBC suffice initially. The AAD and international guidelines recommend against routine extensive allergy testing or food elimination diets, as >95% of CU cases have no identifiable external trigger and such testing is rarely helpful. Testing is appropriate only if specific triggers are suspected (e.g., penicillin allergy if patient recently took antibiotics before urticaria onset).

Targeted testing should include:

• Thyroid function (TSH, TPO antibodies) given 30-60% association with thyroid disease
• Hepatitis B and C serology (if risk factors or concern for infection)
• Helicobacter pylori testing (variable geographic relevance; treatment may help in endemic regions)
• Autologous serum skin test (ASST): inject patient's own serum intradermally; wheal formation suggests autoimmune urticaria, though positive test doesn't change management
• Skin biopsy only if atypical features suggest urticarial vasculitis (biopsy shows leukocytoclastic vasculitis instead of normal urticaria histology)

ESR/CRP elevation or systemic symptoms suggest alternative diagnoses (vasculitis, serum sickness, DRESS syndrome) warranting investigation.

Treatment Algorithm

First-line: Modern second-generation (non-sedating) H1 antihistamines. Cetirizine 10 mg daily, loratadine 10 mg daily, or fexofenadine 180 mg daily are FDA-approved for CU. Efficacy rates are 40-50% with monotherapy. Dosing at standard approved doses is appropriate; higher doses (2-3x standard) are not FDA-approved but some evidence supports improved efficacy in 10-30% of patients who fail standard dosing. Continuous dosing (not PRN) is critical—regular dosing prevents flares, while PRN dosing is less effective. Duration: continue ≥2-4 weeks to assess efficacy before escalation. First-generation antihistamines (diphenhydramine) are sedating and less preferred due to impaired quality of life.

Second-line (if inadequate response to H1 antihistamines alone): Add omalizumab (recombinant anti-IgE monoclonal antibody). FDA-approved for CU in 2014. Dosing: 300 mg SC monthly (some patients benefit from more frequent dosing). Efficacy: 50-70% experience significant improvement (≥50% reduction in hive count). Onset: 4-8 weeks. Particularly effective in patients with elevated baseline IgE or positive autoimmune markers. Cost is significant but insurance typically covers after H1 antihistamine failure.

Alternative second-line: Cyclosporine. 3-5 mg/kg/day divided doses. Effective in 60-80% of cases, with rapid onset (1-2 weeks). Reserved for patients who fail/cannot tolerate omalizumab due to need for monitoring (renal function, blood pressure, drug interactions) and side effects (hypertension, nephrotoxicity, hyperglycemia). Typically used as bridge therapy while waiting for omalizumab to work or in severely symptomatic patients.

Third-line agents: Dupilumab (anti-IL-4 receptor), approved by FDA in 2023 for CU inadequately controlled by H1 antihistamines. Dosing: 400-600 mg SC loading dose, then 200-300 mg SC biweekly. Efficacy comparable to omalizumab. Tacrolimus ointment or systemic corticosteroids (short-term only, not for chronic use due to side effects) may provide adjunctive benefit.

Avoidance strategies: Avoid NSAIDs and ACE inhibitors (both can exacerbate urticaria). Maintain cool environment and avoid heat, exercise, and stress when possible (all can trigger flares). Use antihistamine 1 hour before known triggers (e.g., before exercise in cold urticaria).

Prognosis & Complications

Approximately 50% of patients achieve complete resolution by year 5; 20% by year 1. However, 25-30% have persistent disease >10 years. Complications are primarily from impaired quality of life: depression and anxiety affect 40-50% of patients, sleep disturbance in 60-70%, and work productivity loss in 30-40%. Physical complications (secondary infection from scratching, anaphylaxis with concurrent drug exposure) are rare.

When to See a Dermatologist

Seek dermatology evaluation if wheals persist >6 weeks despite avoidance of obvious triggers. Dermatologists can confirm diagnosis, ensure appropriate testing, and escalate to omalizumab or other advanced therapies if first-line antihistamines are insufficient. Refer urgently if you experience symptoms of anaphylaxis (airway swelling, hypotension, difficulty breathing) or have features suggesting underlying systemic disease.

Frequently Asked Questions

Why do my hives keep coming back if I avoided trigger foods?

In 95% of chronic urticaria cases, external triggers like foods are not responsible. Instead, your immune system is overreactive: your mast cells and basophils are primed to release histamine with minimal provocation. This is an intrinsic problem with your immune cells, not something you're eating or touching. Extensive food testing and elimination diets are not helpful per guidelines and often waste time and money.

Will omalizumab cause immunosuppression?

Omalizumab is an anti-IgE monoclonal antibody that binds free IgE in blood, reducing its availability to bind IgE receptors on mast cells. It does NOT suppress your overall immune system—you will still respond normally to infections and vaccinations. Infection rates are not increased with omalizumab use, making it a safe long-term option.

Why should I avoid NSAIDs if I have chronic urticaria?

NSAIDs (like ibuprofen, naproxen) can trigger or worsen urticaria flares in 20-40% of CU patients. The mechanism involves inhibition of COX enzymes, shifting arachidonic acid metabolism toward leukotriene production, which increases mast cell activation. Acetaminophen is a safer alternative for pain/fever. Always inform your doctor you have urticaria before taking any new medication.

How long do I need to stay on antihistamines?

If your urticaria resolves completely, you can gradually taper antihistamines. However, many patients need to continue antihistamines indefinitely as symptoms recur when stopped. Discuss with your dermatologist about trial of dose reduction or discontinuation to assess if remission is durable. Some patients eventually achieve sustained remission after months to years of treatment.

References